

Vermont Vaccine Purchasing Program Assessment Calculation Worksheet

Column →	A		B	C		D	E
Line ↓	CHILDREN			ADULTS			Comments
	Prior July 2019	July 2020-June 2021		Prior July 2019	July 2020-June 2021		
A. Preliminary Vaccine Cost Estimates							
01.	14,459,368	14,603,489		4,006,697	4,200,397		Estimated costs of vaccines (sheets e & f)
02.	72,297	73,017	0.50%	20,033	21,002	0.50%	Provision for vaccine utilization increase
03.	0	0	0.00%	140,936	147,749	3.50%	¹ Provision for vaccine cost increase (% is annual)
04.	14,531,665	14,676,506		4,167,666	4,369,148		Est. vaccines costs(w/utilization & price adjustments.)
05.	-7,952,652	-7,739,849		-338,378	-338,378		Estimated VFC Award & 317 federal grant
06.	0	0		0	0		Other
07.	6,579,012	6,936,657		3,829,288	4,030,770		Total estimated VVPP vaccine costs
B. Assessable Covered Lives Estimates							
08.	59,649	59,795		342,647	337,444		Assessable covered lives (sheet c)
09.	0	0	0.00%	0	0	0.00%	Leakage (unknown insurer, out of reach entity, etc.)
10.	59,649	59,795		342,647	337,444		Assessable lives actually paying
C. Financial Carry Forwards							
11.	3,685,005	670,948		1,757,395	390,523		Vaccine fund carryforward (sheet d.)
12.	0	0	0.0	0	0	0.0	Amt. retained for liquidity reserve /reserve months
13.	3,685,005	670,948		1,757,395	390,523		Carryforward used to reduce current assessment
D. Operational and Other Fixed Costs							
14.	243,423	256,656	3.70%	141,684	149,138	3.70%	VDH operational cost
15.	108,173	120,779		76,321	70,171		Administrative fees - KidsVax (from sheet b.)
16.	682	719	0.01%	397	418	0.01%	Bad debt allowance
17.	352,278	378,154		218,402	219,727		Sub-total anticipated operating costs
18.	0	0	0.00%	0	0	0.00%	Working capital reserve build-up
19.	0	0	0.00%	0	0	0.00%	Risk reserves
20.	\$ 352,278	\$ 378,154		\$ 218,402	\$ 219,727		Total fixed costs
E. Assessment Calculation							
21.	\$ 6,931,290	\$7,314,811		\$ 4,047,690	\$4,250,496		Total assessment funds needed (Line 7+ Line 20)
22.	\$ (3,685,005)	-\$670,948		\$ (1,757,395)	-\$390,523		Plus carry forward credit
23.	\$ 3,246,285	\$6,643,863		\$ 2,290,295	\$3,859,973		Net assessment funds needed
F. Per Assessable Covered Life Assessment							
24.	\$54.48	\$111.12		\$6.72	\$11.52		Annual assessment per covered life
25.	\$4.54	\$9.26		\$0.56	\$0.96		Monthly assessment per covered life calculated
26.	\$4.54	\$9.26		\$0.56	\$0.96		Monthly assessment per covered life recommended
G. Unexpended Assessments							
27.	682	719		397	418		² Unexpended assessments
H. Various Performance Metrics							
28.	1.64%	1.74%		1.99%	1.74%		Administrative fees - KidsVax as % of vaccine costs
29.	5.34%	5.44%		5.69%	5.44%		VDH operational cost & KV admin. fee as a % of vaccines
30.		103.96%			71.43%		% year to year change in assessment rate
31.	\$ 9.68	\$10.19		\$0.98	\$1.05		³ "Normalized" assessment rate (w/o lines 11, & 18)
32.	113.3%	10.1%		75.8%	9.3%		% Change from monthly assessment rate
33.	\$ 10.07	\$10.60		\$1.02	\$1.09		⁴ Preliminary Assessment projection
34.		14.5%			13.7%		Preliminary Assessment increase
I. Vaccine Cost per Covered Life determination							
35.	\$ 9.19	\$ 9.67		\$ 0.93	\$ 1.00		Vaccine cost calculated

Notes:

- ¹ The CDC contract prices change dates are 4/1 for childhood vaccines and 7/1 for adult vaccines. The child price increase is 0 on Line 3 because VDH anticipates purchasing vaccines administered in April-June 2021 in March 2021, at April 2020 prices. All childhood vaccine cost projections are based on April 2020 CDC pricing. The line 3 provision for cost increases is applied for 12 months for adult vaccines in order to estimate July 2020 CDC prices.
- ² Carryforward cash amounts, if any, will be used for a working capital reserve if needed, and then applied to reduce future assessments unless otherwise directed by VDH.
- ³ This rate assumes that the working capital reserve is adequate and so included no reserves and also no carry forward.
- ⁴ Preliminary projection: This is the normalized assessment rate and one additional year of inflation and utilization changes.

Prior Year's Financial Recap

Column →	A	B	C
Line ↓			
<u>Revenues</u>			
01.	Carryforward from prior year (available cash on hand at 4/1/19)	\$4,712,395	
02.	Prior Year Reconciliation: VVPP assessment collections 4/1/19-6/30/19	\$50,355	
03.	VVPP assessment collections over reconciliation period 7/1/19-3/31/20	\$4,094,703	
04.	Estimated VVPP assessment collections 4/1/20-6/30/20	\$1,293,297	
05.	Total Revenues		\$10,150,750
<u>Expenditures / Allowances</u>			
06.	Prior Year Reconciliation: vaccine purchase 4/1/19-6/30/19	\$58,591	
07.	Total vaccine purchases 7/1/19-3/31/20	\$8,285,196	
08.	Estimated vaccine purchase 4/1/20-6/30/20	\$250,000	
09.	Prior Year Reconciliation: KidsVax 4/1/19-6/30/19	\$0	
10.	KidsVax 7/1/19-3/31/20	\$158,722	
11.	Estimated KidsVax 4/1/20-6/30/20	\$25,771	
12.	Prior Year Reconciliation: VDH operational cost 4/1/19-6/30/19	\$34,823	
13.	VDH operational cost 7/1/19-3/31/20	\$236,221	
14.	Estimated VDH operational cost 4/1/20-6/30/20	\$39,956	
15.	Total Expenditures/Allowances		<u>-\$9,089,279</u>
16.	Vaccine Fund Carryforward ¹ (applied to reduce this year's assessment)		\$1,061,471

Notes:

¹ Excess of revenues (including prior carryforward) over expenditures.

VT DOH Pediatric Vaccine Purchase Estimates
Federal Fiscal Year

Column →
Line ↓

	A	B	C	D	E	F	G	H
	Vaccine	Brand Name	VVPP Cost Per Dose ¹	FFY21 estimated doses	FFY21 estimated cost	FFY20 total estimated doses	FFY20 actual doses distributed 10/1/19-3/31/20	Actual/Estimate as a %
01.	DTaP	Daptacel	\$18.55	800	\$ 14,837	1,160	170	15%
02.		Infanrix	\$19.16	5,000	\$ 95,815	6,330	1,990	31%
03.	DTaP-HepB-IPV	Pediarix	\$60.71	11,000	\$ 667,799	11,150	4,660	42%
04.	DTaP-IPV/Hib	Pentacel	\$61.65	8,500	\$ 524,008	8,000	3,275	41%
05.	DTaP-IPV	Kinrix	\$42.46	4,000	\$ 169,836	4,200	1,740	41%
06.		Quadracel	\$41.80	2,200	\$ 91,953	2,000	970	49%
07.	Hib	ActHIB	\$9.75	15,000	\$ 146,190	17,000	6,640	39%
08.		PedvaxHIB	\$13.51	150	\$ 2,027	0	70	n/a
09.		Hiberix	\$9.46	0	\$ -	0	0	n/a
10.	HepA	Vaqta	\$20.61	0	\$ -	0	0	n/a
11.		Havrix	\$21.11	18,000	\$ 380,034	19,500	7,390	38%
12.	HepB	Recombivax	\$12.53	5,000	\$ 62,650	5,000	1,860	37%
13.		Engerix B	\$17.39	4,000	\$ 69,576	4,000	1,230	31%
14.	HPV	Gardasil	\$187.01	16,000	\$ 2,992,160	18,000	5,000	28%
15.	IPV	IPOL	\$13.85	2,200	\$ 30,470	2,000	1,160	58%
16.	Influenza	Fluzone - Quad	\$13.50	24,000	\$ 324,000	21,750	21,720	100%
17.			\$13.50	24,000	\$ 324,000	21,750	19,480	90%
18.		FluMist	\$18.88	3,000	\$ 56,640	7,000	1,790	26%
19.		Fluarix	\$13.75	7,000	\$ 96,250	7,250	8,580	118%
20.		FluLaval	\$13.75	7,000	\$ 96,250	7,250	7,250	100%
21.	MMR	MMR II	\$21.71	7,500	\$ 162,810	8,000	2,380	30%
22.	MMRV	ProQuad	\$137.52	7,500	\$ 1,031,370	7,200	2,850	40%
23.	MCV4 / MenACWY	Menactra	\$96.23	12,500	\$ 1,202,900	11,500	4,790	42%
24.		Menveo	\$95.78	100	\$ 9,578	30	15	50%
25.	MENB	Trumenba	\$114.36	0	\$ -	0	0	n/a
26.		Bexsero	\$120.24	3,000	\$ 360,720	2,500	587	23%
27.	PCV13	Prevnar 13	\$143.82	24,000	\$ 3,451,680	25,000	10,190	41%
28.	PPSV23	Pneumovax 23	\$59.12	200	\$ 11,824	200	104	52%
29.	RV	RotaTeq	\$71.88	7,500	\$ 539,100	7,000	3,510	50%
30.		Rotarix	\$97.51	5,500	\$ 536,294	6,000	2,260	38%
31.	Td	TDVAX	\$16.34	800	\$ 13,074	900	250	28%
32.	Tdap	Boostrix	\$33.14	7,200	\$ 238,608	7,200	3,270	45%
33.		Adacel	\$32.63	2,500	\$ 81,585	2,500	1,180	47%
34.	VAR	Varivax	\$109.26	7,500	\$ 819,450	7,000	2,490	36%
35.				242,650	\$14,603,489	248,370	128,851	

¹ CDC pediatric vaccine contract prices as of 4/1/20

19-20 flu season distribution 9/1/19-3/31/20

Estimated VFC portion **53.0%**

\$7,739,849

VT DOH Adult Vaccine Purchase Estimates
Federal Fiscal Year

Column →
Line ↓

	A	B	C	D	E	F	G	H
	Vaccine	Brand Name	VVPP Cost Per Dose ¹	FFY21 estimated doses	FFY21 estimated cost	FFY20 total estimated doses	FFY20 actual doses distributed 10/1/19-3/31/20	Actual/Estimate as a %
01.	HepA	Vaqta	\$30.758	1,700	\$52,289	0	880	n/a
02.		Havrix	\$30.758	3,900	\$119,956	4700	1820	39%
03.	HepB	Engerix B	\$33.515	2,500	\$83,788	4000	1070	27%
04.	HepB	Hepelisav-B	\$69.750	2,500	\$174,375	1500	490	33%
05.	HepA-HepB	Twinrix	\$61.858	1,500	\$92,787	2000	570	29%
06.	HPV	Gardasil	\$140.587	4,500	\$632,642	4100	1620	40%
07.	Influenza	Fluarix	\$12.450	22,500	\$280,125	25000	24680	99%
08.		FluLaval	\$12.450	22,500	\$280,125	25000	14780	59%
09.	MMR	MMR II	\$48.861	500	\$24,431	500	170	34%
10.	MCV4 / MenACWY	Menactra	\$75.066	1,000	\$75,066	1000	315	32%
11.		Menveo	\$67.618	0	\$0	0	0	n/a
12.	MENB	Trumenba	\$75.814	0	\$0	0	0	n/a
13.		Bexsero	\$103.938	550	\$57,166	500	126	25%
14.	PCV13	Pprevnar 13	\$125.070	1,500	\$187,605	2000	370	19%
15.	PPSV23	Pneumovax 23	\$62.689	5,000	\$313,445	5000	2199	44%
16.	RZV	Shingrix	\$102.316	12,000	\$1,227,792	12000	4860	41%
17.	Td	TDVAX	\$16.027	7,000	\$112,189	7500	3681	49%
18.	Tdap	Boostrix	\$25.100	14,750	\$370,225	14500	5180	36%
19.		Adacel	\$24.491	4,250	\$104,087	4000	1720	43%
20.	VAR	Varivax	\$82.039	150	\$12,306	140	50	36%
21.				108,300	\$4,200,397	113,440	64,581	

¹ CDC adult vaccine contract purchase prices as of 4/1/20

19-20 flu season distribution 9/1/19-3/31/20

estimated 317 \$338,378